艾伏尼布多久会耐药,应该怎么处理?

Ivonib is a powerful oral targeted inhibitor for cancers with IDH1 gene mutations. By reversibly combining with mutated IDH1, it reduces the level of the tumor metabolite 2-HG and promotes normal cell differentiation, thereby exerting anti-tumor effects. Originally developed by Agios, Servier acquired the rights to the product through the acquisition of Agios' oncology business. So, how long will it take for resistance to ivonib to develop, and how should it be treated?

How long does it take for resistance to ivonib to develop?

Ivonib can be used to treat patients with locally advanced or metastatic cholangiocarcinoma with IDH1 mutations, and can also be used in adult patients with acute myeloid leukemia (AML) with IDH1 mutations, including adults with relapsed or refractory AML and newly diagnosed patients aged ≥75 years or older. For adult patients who cannot use intensive induction chemotherapy due to comorbidities, it can improve the patient's quality of life and prolong the patient's survival. However, ivonib will also be resistant. Since each patient's constitution and disease progression are different, the time and manifestation of drug resistance in patients are also different.

How to deal with resistance to ivonib

Drug resistance is a common phenomenon in the treatment of almost all diseases, especially in the treatment of some chronic diseases that require long-term medication; it is most common in antibiotic treatment, hepatitis B antiviral treatment, tumor chemotherapy, and immune disease treatment. Once drug resistance occurs, the therapeutic effect of the drug is significantly reduced. If the effect of ivonib decreases during treatment and the condition becomes more serious instead of relieved, it is considered that drug resistance has developed. If ivosidenib becomes resistant, you should consult the relevant doctor as soon as possible to change or replace the treatment plan without delay, so as not to affect the treatment.

Ivonib plays an important role in the treatment of advanced tumors. On February 9, 2022, the drug was approved in mainland China for the treatment of adult patients with relapsed or refractory acute myeloid leukemia who carry IDH1 susceptibility mutations. The above is the content of how long it will take to become resistant to ivonib and what should be done after resistance.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: